<?xml version="1.0" encoding="UTF-8"?>
<p>A total of 4 neuraminidase inhibitors (NAIs) are currently used in hospitals and clinics in Japan. These include oseltamivir, zanamivir, the inhaled drug, laninamivir, and the intravenous drug, peramivir. Moreover, a new RNA polymerase inhibitor, baloxavir marboxil, was approved in 2018, and was widely used in the 2018â€“19 season [
 <xref rid="pone.0231217.ref004" ref-type="bibr">4</xref>]. It was reported that over 5 million people were treated with baloxavir in Japan.
</p>
